123 related articles for article (PubMed ID: 10406511)
1. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients.
Aguilera A; Selgas R; Ruiz-Caravaca ML; Bajo MA; Cuesta MV; Plaza MA; Hernanz A
Perit Dial Int; 1999; 19 Suppl 2():S161-6. PubMed ID: 10406511
[TBL] [Abstract][Full Text] [Related]
2. Malnutrition-inflammation syndrome is associated with endothelial dysfunction in peritoneal dialysis patients.
Aguilera A; Sánchez-Tomero JA; Bajo MA; Ruiz-Caravaca ML; Alvarez V; del Peso G; Herranz A; Cuesta MV; Castro MJ; Selgas R
Adv Perit Dial; 2003; 19():240-5. PubMed ID: 14763071
[TBL] [Abstract][Full Text] [Related]
3. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
[TBL] [Abstract][Full Text] [Related]
4. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
5. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients.
Aguilera A; Bajo MA; Díez JJ; Ruiz-Caravaca ML; Vicenta Cuesta M; Alvarez V; Codoceo R; Selgas R
Adv Perit Dial; 2002; 18():200-5. PubMed ID: 12402619
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
Borawski J; Myśliwiec M
Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
[TBL] [Abstract][Full Text] [Related]
7. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertensive 5/6 nephrectomized rat aorta.
Toba H; Morishita M; Tojo C; Nakano A; Oshima Y; Kojima Y; Yoshida M; Nakashima K; Wang J; Kobara M; Nakata T
Eur J Pharmacol; 2011 Apr; 656(1-3):81-7. PubMed ID: 21296066
[TBL] [Abstract][Full Text] [Related]
10. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
Nagai T; Akizawa T; Kohjiro S; Koiwa F; Nabeshima K; Niikura K; Kino K; Kanamori N; Kinugasa E; Ideura T
Kidney Int; 1996 Jul; 50(1):102-7. PubMed ID: 8807578
[TBL] [Abstract][Full Text] [Related]
11. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
[TBL] [Abstract][Full Text] [Related]
12. Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis.
Gündüz Z; Kisaarslan FA; Düsünsel R; Poyrazoglu HM; Saraymen R; Per H
Adv Perit Dial; 1999; 15():278-82. PubMed ID: 10682118
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
[TBL] [Abstract][Full Text] [Related]
14. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.
Andrianto ; Al-Farabi MJ; Nugraha RA; Marsudi BA; Azmi Y
Microvasc Res; 2021 Nov; 138():104224. PubMed ID: 34273359
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
Borawski J; Naumnik B; Mysliwiec M
Clin Appl Thromb Hemost; 2002 Oct; 8(4):359-67. PubMed ID: 12516686
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin and sexual dysfunction.
Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J
Nephrol Dial Transplant; 1997 Apr; 12(4):741-7. PubMed ID: 9141005
[TBL] [Abstract][Full Text] [Related]
18. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis.
Takagi M; Wada H; Mukai K; Kihira H; Yano S; Minamikawa K; Wakita Y; Nakase T; Nagaya S; Deguchi K
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):713-7. PubMed ID: 7865676
[TBL] [Abstract][Full Text] [Related]
19. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
Takahashi H; Ito S; Hanano M; Wada K; Niwano H; Seki Y; Shibata A
Am J Hematol; 1992 Sep; 41(1):32-9. PubMed ID: 1323930
[TBL] [Abstract][Full Text] [Related]
20. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
